Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a wearable glucose monitor improve daily diabetes care? a 5,000-Person study seeks answers

NCT ID NCT06483945

Knowledge-focused Sponsor: DexCom, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This study follows 5,000 people with diabetes who use a Dexcom continuous glucose monitoring (CGM) system in their daily routine. Researchers will track how the device performs when used as labeled and ask participants to complete questionnaires over four years. The goal is to understand the real-world impact of CGM on users' lives and diabetes management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dexcom continuous glucose monitoring (CGM) system, including G6, G6 Pro, and G7 devices
What this could lead to
If successful, this study could provide real-world evidence on how Dexcom CGM devices perform outside clinical trials, potentially guiding better diabetes management and device improvements.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results depend on self-reported data and may not apply to all users.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The clinical study population will consist of up to 5000 subjects.

Ages

2 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Meets Dexcom CGM System Indications for Use (IFU) per approved commercial labeling * Has at least one HbA1C (Hemoglobin a1c) measurement within three (3) months prior to the Dexcom CGM System use start date that is at least three (3) months after any prior CGM use * Subject is willing and able to use Dexcom CGM System according to approved product labeling * Subject is willing and able to complete applicable patient reported outcome assessments/ surveys * Subject is willing and able to comply with the protocol * Subject is willing and able to comply with provider requirements for at least two provider encounters per year according to applicable clinical practice guidelines * Subject or the subject's legally authorized representative must provide written informed consent prior to any study-related data collection or be enrolled under an IRB/EC approved waiver of consent Exclusion Criteria: * Is contraindicated for a Dexcom CGM System per approved commercial labeling * In the Investigator's opinion, the subject is not considered to be a suitable candidate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes

Contacts and locations

Locations

  • Institute of Endocrinology Diabetes, Health & Hormones

    Stockbridge, Georgia, 30281, United States

  • Palm Research Center

    Las Vegas, Nevada, 89148, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.